Related Experiment Video

Updated: Nov 30, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

Italia Falcone1, Fabiana Conciatori1, Chiara Bazzichetto1

  • 1Medical Oncology 1, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.

International Journal of Molecular Sciences
|November 13, 2020
PubMed

Insights

AXL, a key biomarker in breast cancer, shows promise as a therapeutic target. Its role in tumor progression and immune modulation makes it crucial for developing new targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Breast cancer therapy has advanced with targeted treatments like HER2 inhibitors.
  • Identifying novel biomarkers is crucial for improving patient outcomes.
  • AXL, a TAM family receptor tyrosine kinase, is recognized as a significant biomarker in various cancers, including breast cancer.

Purpose of the Study:

  • To review the biological functions of AXL in breast tumor cells.
  • To highlight AXL's molecular and biological characteristics.
  • To discuss AXL's role in tumor progression and its potential as a therapeutic target.

Main Methods:

  • Literature review of AXL's role in breast cancer.
  • Analysis of AXL's molecular and biological features.
  • Examination of AXL's involvement in tumor progression and the tumor microenvironment.

Main Results:

  • AXL functions as a predictive and prognostic biomarker in breast cancer.
  • AXL plays a role in oncogenesis and tumor progression.
  • AXL exhibits immune-modulatory functions within the tumor microenvironment.

Conclusions:

  • AXL is a critical target for novel pharmacological agents in breast cancer treatment.
  • AXL's multifaceted roles warrant further investigation in ongoing clinical trials.
  • Understanding AXL's biology is essential for advancing breast cancer targeted therapy and immunotherapy.
Keywords:
AXLbiomarkersbreast cancerimmunotherapytargeted therapytumor microenvironment

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.4K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.6K